Emergent BioSolutions (United Kingdom)

Emergent BioSolutions (United Kingdom)

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Emergent BioSolutions (United Kingdom), United Kingdom, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

89%


Total
Publications

65


Total Open
Publications

58


Total
Citations

461


Open Access
Percentage

89%


Total
Publications

65


Total Open
Publications

58


Total
Citations

461

Wikipedia

Website

download

Breakdown

60% 20% 9% 11%

Publisher Open

60%

Both

20%

Other Platform Open

9%

Closed

11%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820222426Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

21%OA Journal

OA Journal 21%

11

Hybrid 14%

7

No Guarantees 65%

34

Other Platform Open

Institution 68%

13

Domain 37%

7

Public 21%

4

Other Internet 21%

4

Preprint 11%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
7
Europe PMC
Domain
6
University of Oxford - Oxford University Research Archive (ORA)
Institution
5
whiterose.ac.uk OAI-PMH Repository
Institution
3
St George's University of London - St George's Online Research Archive
Institution
3
CiteSeer X
Other Internet
3
University of Birmingham - University of Birmingham Research Portal
Institution
2
unimelb.edu.au OAI-PMH Repository
Institution
2
Open Research Library
Public
2
Zenodo
Public
1
1 / 3

Data updated 13 May 2024

Share

Share

Share